← 返回前沿论文

线粒体适应度作为癌症中的功能性免疫检查点:代谢可塑性、肿瘤演化与免疫治疗

英文原题:Mitochondrial Fitness as a Functional Immune Checkpoint in Cancer: Metabolic Plasticity, Tumor Evolution, and Immunotherapy.

PubMed 2026/09/01(内容时间) Cancers (Basel) Q2 · IF 4.8(JCR 2025)

研究概要

线粒体日益被认为是癌细胞适应、免疫功能和治疗反应的动态调节因子。

中文摘要

线粒体日益被认为是癌细胞适应、免疫功能和治疗反应的动态调控因子。除了在能量产生中的经典作用外,线粒体代谢、动力学、质量控制和应激信号还影响肿瘤细胞的存活以及免疫效应细胞在肿瘤微环境中维持抗肿瘤活性的能力。在这篇叙述性综述中,我们将线粒体适应性视为一种多维功能属性,涵盖生物能量能力、代谢灵活性、氧化还原稳态、线粒体质量控制以及对细胞应激和治疗应激的适应。我们提出线粒体功能免疫检查点这一概念框架,将恶性细胞和免疫细胞中的线粒体适应性与肿瘤-免疫相互作用及免疫治疗反应联系起来。我们讨论线粒体代谢可塑性、线粒体应激和 mtDNA 信号、活性氧、线粒体动力学以及细胞间线粒体转移如何促进免疫逃逸和治疗耐药。我们进一步探讨线粒体适应性与免疫检查点阻断、CAR-T 细胞治疗和 T 细胞重定向双特异性抗体的相关性,特别关注血液系统恶性肿瘤,包括急性髓系白血病和多发性骨髓瘤,同时纳入部分实体瘤证据,以突出共同的线粒体机制及其更广泛的肿瘤学意义。最后,我们讨论线粒体靶向和功能性线粒体分析的新兴策略,以及它们与已建立的分子评估和可测量残留病灶评估整合的潜力。当前证据支持线粒体生物学作为精准肿瘤学的一个补充维度,尽管在情境依赖性、生物标志物标准化、治疗选择性以及免疫细胞适应性保护方面仍存在重要挑战。需要前瞻性研究来确定功能性线粒体谱分析能否改善患者分层,并指导合理的治疗组合,从而在保留有效抗肿瘤免疫的同时,选择性利用肿瘤线粒体脆弱性。

展开英文摘要原文

Mitochondria are increasingly recognized as dynamic regulators of cancer-cell adaptation, immune function, and therapeutic response. Beyond their canonical role in energy production, mitochondrial metabolism, dynamics, quality control, and stress signaling influence tumor-cell survival and the capacity of immune effector cells to sustain antitumor activity within the tumor microenvironment. In this narrative review, we examine mitochondrial fitness as a multidimensional functional property encompassing bioenergetic capacity, metabolic flexibility, redox homeostasis, mitochondrial quality control, and adaptation to cellular and therapeutic stress. We propose the mitochondrial functional immune checkpoint as a conceptual framework linking mitochondrial fitness in malignant and immune cells to tumor-immune interactions and immunotherapy response. We discuss how mitochondrial metabolic plasticity, mitochondrial stress and mtDNA signaling, reactive oxygen species, mitochondrial dynamics, and intercellular mitochondrial transfer contribute to immune escape and treatment resistance. We further examine the relevance of mitochondrial fitness to immune checkpoint blockade, CAR-T-cell therapy, and T-cell-redirecting bispecific antibodies, with particular attention to hematological malignancies, including acute myeloid leukemia and multiple myeloma, while incorporating selected evidence from solid tumors to highlight shared mitochondrial mechanisms and their broader oncologic relevance. Finally, we discuss emerging strategies for mitochondrial targeting and functional mitochondrial profiling and their potential integration with established molecular and measurable residual disease assessments. Current evidence supports mitochondrial biology as a complementary dimension of precision oncology, although important challenges remain regarding context dependence, biomarker standardization, therapeutic selectivity, and preservation of immune-cell fitness. Prospective studies are needed to determine whether functional mitochondrial profiling can improve patient stratification and guide rational therapeutic combinations that selectively exploit tumor mitochondrial vulnerabilities while preserving effective antitumor immunity.

论文信息

作者
Morabito F、Martino EA、Bruzzese A、Amodio N、Vigna E、Gentile M
第一作者单位
Dafne Srl, 89048 Reggio Calabria, Italy.Italy
通讯作者单位
Hematology Unit, Department of Onco-Hematology, AO Hospital of Cosenza, 87100 Cosenza, Italy.Italy
文献类型
综述
期刊
Cancers2026 Sep 1
原文标识
PubMed 42738339 · DOI 10.3390/cancers18172818